Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Deal Details:
Takeda has paid Keros Therapeutics $200 million upfront for ex-China rights to a molecule that could compete with Bristol Myers Squibb's (BMS) blockbuster drug Reblozyl234.
Potential Milestones:
The deal includes up to $1.1 billion in potential milestones, indicating significant investment in the development of this rival drug34.
Impact on BMS:
This move by Takeda could potentially challenge BMS' market share for Reblozyl, a drug used in the treatment of certain cancers23.
Strategic Move:
Takeda's acquisition is part of its strategy to bolster its late-stage cancer pipeline, aiming to strengthen its position in the oncology market4.
Market Context:
The pharmaceutical industry is witnessing significant investments and strategic partnerships, with companies like Takeda and BMS competing for dominance in the cancer treatment sector23.
Sources:
2. https://www.finanznachrichten.de/nachrichten-aktien/bristol-myers-squibb-company.htm
3. https://cafepharma.com/boards/threads/takeda-pays-keros-200m-upfront-for-rival-to-bms-039-booming-blockbuster-reblozyl.705116/